Adjuvant treatment of novel multiple cancer vaccine restricted with HLA-A24 for patients with completely resected non-small cell lung cancer. randomized phase II trial
Phase 2
Recruiting
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000009380
- Lead Sponsor
- Fukushima Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1. With uncontrollable ischemic heart disease and/or arhythmia 2. With acute myocardial infarction 6 months before treatment 3. Lactating, pregnant or possibly pregnant women, or those willing to become pregnant 4. With double cancer, multiple cancer 5. With active inflammatory disease 6. With steroidal or immunosuppressive agent dependency 7. Physician concludes that the patient's participation in this trial is inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence free survival
- Secondary Outcome Measures
Name Time Method Overall survival Antigen specific T cell responses